Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy.

ABSTRACT: Patients with hepatocellular carcinoma (HCC) at the same clinical stage can have extremely different prognoses, and molecular subtyping provides an opportunity for individualized precision treatment. In this study, genomic, transcriptomic, proteomic, and phosphoproteomic profiling of primary tumor tissues and paired para-tumor tissues from HCC patients (N = 160) are integrated. Proteomic profiling identifies three HCC subtypes with different clinical prognosis, which are validated in three publicly available external validation sets. A simplified panel of nine proteins associated with metabolic reprogramming is further identified as a potential subtype-specific biomarker for clinical application. Multi-omics analysis further reveals that three proteomic subtypes have significant difference

SUBMITTER: Xing X 

PROVIDER: S-EPMC10783603 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature